{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/optimizing-efficiencies-and-reducing-white-space-across-phase-i-phase-iii-oncology#webpage",
"url": "https://www.fortrea.com/insights/optimizing-efficiencies-and-reducing-white-space-across-phase-i-phase-iii-oncologyr",
"name": "Optimizing efficiencies and reducing white space across Phase I to Phase III in an oncology clinical trial",
"description": "This Fortrea case study examines how a lymphoma development program achieved greater efficiency across Phase I, Phase II, and Phase III oncology clinical trials through a consultative and scientifically driven approach focused on operational continuity and reducing development white space. Supporting five studies across the program, Fortrea established a consistent operational framework that enabled seamless progression between study phases, reduced transition gaps, and maintained continuity throughout a highly complex oncology development landscape. The team leveraged strong site relationships, global feasibility expertise, flexible resource scaling, dedicated compound management support, efficient Phase III and first-patient-in planning, and a cross-study data cleaning task force to improve data readiness across the program. By integrating processes and knowledge across studies rather than treating each phase independently, Fortrea helped streamline startup activities, support milestone achievement, optimize operational efficiencies, and deliver significant time and cost savings while advancing the sponsor’s lymphoma clinical development strategy from First-in-Human studies through Phase III."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Optimizing efficiencies and reducing white space across Phase I to Phase III in an oncology clinical trial",
"item": "https://www.fortrea.com/insights/optimizing-efficiencies-and-reducing-white-space-across-phase-i-phase-iii-oncology"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/optimizing-efficiencies-and-reducing-white-space-across-phase-i-phase-iii-oncology#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/optimizing-efficiencies-and-reducing-white-space-across-phase-i-phase-iii-oncology#webpage"
},
"headline": "Optimizing efficiencies and reducing white space across Phase I to Phase III in an oncology clinical trial",
"description": "This Fortrea case study examines how a lymphoma development program achieved greater efficiency across Phase I, Phase II, and Phase III oncology clinical trials through a consultative and scientifically driven approach focused on operational continuity and reducing development white space. Supporting five studies across the program, Fortrea established a consistent operational framework that enabled seamless progression between study phases, reduced transition gaps, and maintained continuity throughout a highly complex oncology development landscape. The team leveraged strong site relationships, global feasibility expertise, flexible resource scaling, dedicated compound management support, efficient Phase III and first-patient-in planning, and a cross-study data cleaning task force to improve data readiness across the program. By integrating processes and knowledge across studies rather than treating each phase independently, Fortrea helped streamline startup activities, support milestone achievement, optimize operational efficiencies, and deliver significant time and cost savings while advancing the sponsor’s lymphoma clinical development strategy from First-in-Human studies through Phase III.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-05-12",
"dateModified": "2026-05-12",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-05/phase-1-to-phase-3-oncology-trial-efficiency-case-study.pdf",
"encodingFormat": "application/pdf"
}
}
]
}